TY - JOUR T1 - Dasatinib-induced Seborrheic Dermatitis-like Eruption. AU - Riahi,Ryan R, AU - Cohen,Philip R, Y1 - 2017/07/01/ PY - 2017/11/7/entrez PY - 2017/11/7/pubmed PY - 2017/11/7/medline KW - Antineoplastic KW - BRAF KW - c-kit KW - chemotherapy KW - cutaneous KW - dasatinib KW - melanoma KW - mucocutaneous KW - mucosal KW - seborrheic dermatitis KW - side effect KW - tyrosine kinase inhibitors SP - 23 EP - 27 JF - The Journal of clinical and aesthetic dermatology JO - J Clin Aesthet Dermatol VL - 10 IS - 7 N2 - Dasatinib is an oral tyrosine kinase inhibitor approved for imatinib-resistant chronic myelogenous leukemia. It has been investigated in treating other neoplasms, including non-small-cell lung cancer and a subset of melanomas. Seborrheic dermatitis is characterized by erythematous patches or plaques with scaling typically affecting the external ear, glabella, hair-bearing areas of the face, nasolabial fold, and scalp. Antitumor agents are often associated with mucocutaneous side effects, including seborrheic dermatitis. We describe the case of a 79-year-old woman with a history of sinonasal melanoma who developed a seborrheic dermatitis-like eruption while taking dasatinib. We also review the molecular abnormalities associated with melanoma, summarize the mucocutaneous side effects of dasatinib, and list the other antineoplastic agents associated with a seborrheic dermatitis-like eruption. SN - 1941-2789 UR - https://www.unboundmedicine.com/medline/citation/29104720/Dasatinib_induced_Seborrheic_Dermatitis_like_Eruption_ DB - PRIME DP - Unbound Medicine ER -